Abstract
Background: Concerns regarding the autoimmune safety of COVID-19 vaccines may negatively impact vaccine uptake. We aimed to describe the incidence of autoimmune conditions following BNT162b2 and CoronaVac vaccination and compare these with age-standardized incidence rates in non-vaccinated individuals.
Methods: This is a descriptive cohort study conducted in public healthcare service settings. Territory-wide longitudinal electronic medical records of Hong Kong Hospital Authority users (≥16 years) were linked with COVID-19 vaccination records between February 23, 2021 and June 30, 2021. We classified participants into first/second dose BNT162b2 groups, first/second dose CoronaVac groups and non-vaccinated individuals for incidence comparison. The study outcomes include hospitalized autoimmune diseases (16 types of immune-mediated diseases across six body systems) within 28 days after first and second dose of vaccination. Age-standardized incidence rate ratios (IRRs) with exact 95% confidence intervals (CIs) were estimated using Poisson distribution.
Results: This study included around 3.9 million Hong Kong residents, of which 1,122,793 received at least one dose of vaccine (BNT162b2: 579,998; CoronaVac: 542,795), and 721,588 completed two doses (BNT162b2: 388,881; CoronaVac: 332,707). Within 28 days following vaccination, cumulative incidences for all autoimmune conditions were below 9 per 100,000 persons, for both vaccines and both doses. None of the age-standardized incidence rates were significantly higher than the non-vaccinated individuals, except for an observed increased incidence of hypersomnia following the first dose of BNT162b2 (standardized IRR: 1.47; 95% CI: 1.10-1.94).
Conclusions: Autoimmune conditions requiring hospital care are rare following mRNA and inactivated COVID-19 vaccination with similar incidence to non-vaccinated individuals. The association between first dose BNT162b2 vaccination and immune-related sleeping disorders requires further research. Population-based robust safety surveillance is essential to detect rare and unexpected vaccine safety events.
Keywords: Autoimmune diseases; COVID-19 vaccines; Inactivated virus vaccine; Pharmacovigilance; mRNA vaccine.
【저자키워드】 mRNA vaccine, pharmacovigilance, COVID-19 vaccines, Autoimmune diseases, Inactivated virus vaccine, 【초록키워드】 COVID-19, Vaccine, COVID-19 vaccine, vaccination, Hospitalized, mRNA vaccine, hospital, CoronaVac, virus, cohort study, BNT162b2, Autoimmune disease, COVID-19 vaccination, Surveillance, mRNA, healthcare, Research, incidence rate, Autoimmune, incidence, Hong Kong, group, concern, Care, inactivated, association, Poisson distribution, dose, autoimmune condition, 95% confidence interval, second dose, first dose, individual, participant, doses, disorder, cumulative, authority, electronic medical record, immune-mediated disease, robust, detect, include, conducted, events, condition, significantly higher, individuals, groups, CIs, of BNT162b2, study outcome, with COVID-19, 【제목키워드】 COVID-19, CoronaVac, cohort study, BNT162b2, mRNA, Hong Kong, inactivated, condition,